Zyvox (linezolid) Tablets, I.V., & Suspension, Pharmacia & Upjohn NDA 21-130/S3, 21-131/S3 & 21-132/S3 12/19/02 1/29/03 4/7/03 Zyvox (linezolid) Tablets, I.V., & Suspension, Pharmacia & Upjohn NDA 21-130/S2, 21-131/S2 & 21-132/S2 12/19/02 1/29/03 4/7/03 Zyvox (linezolid) Tablets, I.V., & Suspension, 400 & 600 mg Tablets; I.V. 200 mg/100 mL, 400 mg/200 mL, & 600 mg/300 mL bags; Suspension, 100 mg/5 mL Pharmacia & Upjohn NDA 21-130, 31, 32 4/18/00 4/24/00 4/24/00 1/29/02 Zyvox Indications: The treatment of adult patients with vancomycin-resistant Enterococcus faeciuminfections, nosocomial pneumonia, complicated and uncomplicated skin and skin structure infections, and community-acquired pneumonia. Zyvox (linezolid) Tablets, I.V., & Oral Suspension, Pharmacia & Upjohn Zyvox (linezolid) IV Injection Pharmacia & Upjohn Company | Zyvox (linezolid) Oral Suspension Pharmacia & Upjohn Company | Zyvox (linezolid) Tablets Pharmacia & Upjohn Company | Zyvox (linezolid) IV Injection, Pharmacia & Upjohn, Labeling Revision | Zyvox (linezolid) Oral Suspension, Pharmacia & Upjohn, Labeling Revision | Zyvox (linezolid) Tablets, Pharmacia & Upjohn, Labeling Revision

For the most up-to-date approval information, please locate this API using the drug index. For industry specific content, please visit USActives.com.